Alison Kanski

3 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Bristol Myers Squibb's CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) continued its exponential growth in Q1, with sales more than doubling in the US and tripling in international markets, driven by expanding indications in leukemias and lymphomas. BMS CFO David Elkins cited Breyanzi as a "key contributor" to the positive performance of the firm's growth portfolio, which includes its newer medicines that don't have generic competition.

3 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – While targeted therapies can dramatically shrink tumors for patients, the benefits are often temporary and patients inevitably acquire mutations that help cancer cells survive, requiring a different treatment approach.

3 weeks ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Researchers have developed a blood-based test for predicting whether non-Hodgkin lymphoma patients will respond to autologous CAR T-cell therapy prior to starting treatment. The researchers published results from a training and validation study of the predictive tool, called InflaMix, in Nature Medicine earlier this month.

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – ALX Oncology has brought its second candidate therapy into the clinic, a potential first-in-class EGFR-targeted antibody-drug conjugate (ADC) that could help reduce toxicity for patients with EGFR-mutant tumors. The US Food and Drug Administration cleared the firm's investigational new drug application this week, allowing ALX to begin a Phase I trial of the drug, dubbed ALX2004, in EGFR-expressing solid tumors. ALX CEO Jason Lettmann said the firm expects to begin the trial mid-year.

1 month ago | precisionmedicineonline.com | Alison Kanski

NEW YORK – Results from an arm of the NCI-MATCH trial evaluating AstraZeneca's AKT inhibitor Truqap (capivasertib) in AKT1 E17K-mutated solid tumors demonstrated activity for the drug in gynecological as well as breast cancer and identified potential biomarkers of response. The cohort, called arm Y of NCI-MATCH precision medicine basket trial, enrolled 35 patients with a range of solid tumors harboring AKT1 E17K mutations.